Position in EXEL
as of Mar 31, 2026
· filed Apr 20, 2026
Position Value
$583,990
-$32,522 QoQ
Shares Held
13,616
-3.2% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
3 quarters on record
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026KESTRA PRIVATE WEALTH SERVICES, LLC holds $9,792,733 across 21 Biotechnology names. EXEL ranks #5 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
9,675 | $4,320,274 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
50,588 | $956,113 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
993 | $767,231 | |
| 4 | INCY |
Incyte Corp
|
7,196 | $677,287 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
13,616 | $583,990 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
11,064 | $526,314 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
11,191 | $364,155 | |
| 8 | ARQT |
Arcutis Biotherapeutics, Inc.
|
11,729 | $276,335 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $583,990 | 13,616 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $616,512 | 14,066 | Shares | Sole | 2026-01-29 | |
| 2025-06-30 | $213,082 | 4,834 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||